NASDAQ:ANIP - ANI Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $51.99 -0.11 (-0.21 %) (As of 11/15/2018 04:00 PM ET)Previous Close$52.10Today's Range$50.53 - $52.7552-Week Range$48.40 - $74.70Volume54,750 shsAverage Volume99,354 shsMarket Capitalization$620.56 millionP/E Ratio14.40Dividend YieldN/ABeta2.64 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota. Receive ANIP News and Ratings via Email Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A Webwww.anipharmaceuticals.com Phone218-634-3500 Debt Debt-to-Equity Ratio1.04 Current Ratio3.34 Quick Ratio2.49 Price-To-Earnings Trailing P/E Ratio14.40 Forward P/E Ratio11.45 P/E GrowthN/A Sales & Book Value Annual Sales$176.84 million Price / Sales3.48 Cash Flow$5.9282 per share Price / Cash8.77 Book Value$16.27 per share Price / Book3.20 Profitability EPS (Most Recent Fiscal Year)$3.61 Net Income$-1,070,000.00 Net Margins0.23% Return on Equity28.39% Return on Assets12.27% Miscellaneous Employees173 Outstanding Shares11,830,000Market Cap$620.56 million OptionableOptionable ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions What is ANI Pharmaceuticals' stock symbol? ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP." How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals Inc (NASDAQ:ANIP) announced its quarterly earnings results on Tuesday, November, 6th. The specialty pharmaceutical company reported $1.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.12. The specialty pharmaceutical company had revenue of $50.70 million for the quarter, compared to analysts' expectations of $50.97 million. ANI Pharmaceuticals had a return on equity of 28.39% and a net margin of 0.23%. The business's revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.11 earnings per share. View ANI Pharmaceuticals' Earnings History. When is ANI Pharmaceuticals' next earnings date? ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for ANI Pharmaceuticals. What guidance has ANI Pharmaceuticals issued on next quarter's earnings? ANI Pharmaceuticals updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided earnings per share guidance of $4.80-5.27 for the period, compared to the Thomson Reuters consensus estimate of $4.91. The company issued revenue guidance of $195-205 million, compared to the consensus revenue estimate of $200.03 million. What price target have analysts set for ANIP? 2 equities research analysts have issued twelve-month price objectives for ANI Pharmaceuticals' shares. Their forecasts range from $70.00 to $74.00. On average, they anticipate ANI Pharmaceuticals' stock price to reach $72.00 in the next year. This suggests a possible upside of 38.5% from the stock's current price. View Analyst Price Targets for ANI Pharmaceuticals. What is the consensus analysts' recommendation for ANI Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANI Pharmaceuticals. Has ANI Pharmaceuticals been receiving favorable news coverage? Headlines about ANIP stock have been trending somewhat negative on Thursday, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ANI Pharmaceuticals earned a news impact score of -1.4 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the stock's share price in the near term. Who are some of ANI Pharmaceuticals' key competitors? Some companies that are related to ANI Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Allakos (ALLK), Supernus Pharmaceuticals (SUPN), Akcea Therapeutics (AKCA), Myokardia (MYOK), Heron Therapeutics (HRTX), Opko Health (OPK), Xencor (XNCR), Prestige Consumer Healthcare (PBH), Global Blood Therapeutics (GBT), Pacira Pharmaceuticals (PCRX), Endocyte (ECYT), Amicus Therapeutics (FOLD), AnaptysBio (ANAB) and Reata Pharmaceuticals (RETA). Who are ANI Pharmaceuticals' key executives? ANI Pharmaceuticals' management team includes the folowing people: Mr. Arthur S. Przybyl, CEO, Pres & Director (Age 61)Mr. Stephen P. Carey, CFO & VP of Fin. (Age 47)Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 55)Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 46)Dr. David J. Sullivan, VP of Quality Operations Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.72%), Dimensional Fund Advisors LP (4.33%), LSV Asset Management (2.49%), First Manhattan Co. (1.82%), Renaissance Technologies LLC (1.51%) and Matarin Capital Management LLC (0.72%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals. Which institutional investors are selling ANI Pharmaceuticals stock? ANIP stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Rice Hall James & Associates LLC, LSV Asset Management, BlackRock Inc., BlueMountain Capital Management LLC, SG Americas Securities LLC, Algert Global LLC and Credit Suisse AG. Company insiders that have sold ANI Pharmaceuticals company stock in the last year include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Insider Buying and Selling for ANI Pharmaceuticals. Which institutional investors are buying ANI Pharmaceuticals stock? ANIP stock was purchased by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, First Manhattan Co., Dimensional Fund Advisors LP, Triarii Capital Management LP, Investment Counselors of Maryland LLC, Panagora Asset Management Inc., Hussman Strategic Advisors Inc. and First Trust Advisors LP. View Insider Buying and Selling for ANI Pharmaceuticals. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ANI Pharmaceuticals' stock price today? One share of ANIP stock can currently be purchased for approximately $51.99. How big of a company is ANI Pharmaceuticals? ANI Pharmaceuticals has a market capitalization of $620.56 million and generates $176.84 million in revenue each year. The specialty pharmaceutical company earns $-1,070,000.00 in net income (profit) each year or $3.61 on an earnings per share basis. ANI Pharmaceuticals employs 173 workers across the globe. What is ANI Pharmaceuticals' official website? The official website for ANI Pharmaceuticals is http://www.anipharmaceuticals.com. How can I contact ANI Pharmaceuticals? ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected] MarketBeat Community Rating for ANI Pharmaceuticals (NASDAQ ANIP)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 298 (Vote Outperform)Underperform Votes: 243 (Vote Underperform)Total Votes: 541MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/15/2018 by MarketBeat.com StaffFeatured Article: How is Preferred Stock Different from Common Stock?